Open Access

Effects of SB202190 on expression levels of IL-6 and NF-κB in flap ischemia-reperfusion injury

  • Authors:
    • Kai Guo
    • Jingxin Ma
    • Wenyong Liang
  • View Affiliations

  • Published online on: July 13, 2018     https://doi.org/10.3892/etm.2018.6442
  • Pages: 2522-2526
  • Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the current study was to investigate the effect of SB202190, a specific inhibitor of p38 MAPK signaling pathway, on the expression levels of IL-6 and NF-κB in flap ischemia-reperfusion injury. Healthy Sprague-Dawley rats were randomly divided into four groups of 12 each. For the ischemia-reperfusion group, the flap was constructed and then sutured after 8 h of ischemia. For the saline group, rats were intraperitoneally infused with saline at regular intervals after flap ischemia-reperfusion. For the inhibitor group, rats were intraperitoneally infused with SB202190 at regular intervals after flap ischemia-reperfusion. For the control group, the flap was constructed and then sutured immediately. The flap survival rate of each group was measured after 7 days. The concentration of IL-6 in serum was measured by ELISA kit. The mRNA and protein expression levels of IL-6 and NF-κB in the flap were measured using RT-PCR and western blot analysis, respectively. In the ischemia-reperfusion group and the saline group, the flap survival rates were much lower than that in the control group (P<0.05). By contrast, the mRNA and protein expression levels of IL-6 and NF-κB in the flap and the concentration of IL-6 in serum were much higher (P<0.05). In the inhibitor group, the flap survival rate was significantly higher than those in the ischemia-reperfusion and saline groups (P<0.05). By contrast, the concentration of IL-6 in serum and the mRNA and protein expression levels of NF-κB and IL-6 in the flap were significantly decreased (P<0.05). The results show that, SB202190 played a role in the protection of the flap by reducing the inflammatory response in flap ischemia-reperfusion injury.
View Figures
View References

Related Articles

Journal Cover

September-2018
Volume 16 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Guo K, Ma J and Liang W: Effects of SB202190 on expression levels of IL-6 and NF-κB in flap ischemia-reperfusion injury. Exp Ther Med 16: 2522-2526, 2018.
APA
Guo, K., Ma, J., & Liang, W. (2018). Effects of SB202190 on expression levels of IL-6 and NF-κB in flap ischemia-reperfusion injury. Experimental and Therapeutic Medicine, 16, 2522-2526. https://doi.org/10.3892/etm.2018.6442
MLA
Guo, K., Ma, J., Liang, W."Effects of SB202190 on expression levels of IL-6 and NF-κB in flap ischemia-reperfusion injury". Experimental and Therapeutic Medicine 16.3 (2018): 2522-2526.
Chicago
Guo, K., Ma, J., Liang, W."Effects of SB202190 on expression levels of IL-6 and NF-κB in flap ischemia-reperfusion injury". Experimental and Therapeutic Medicine 16, no. 3 (2018): 2522-2526. https://doi.org/10.3892/etm.2018.6442